Stockreport

HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress

HilleVax, Inc.  (HLVX) 
PDF Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million [Read more]